PL3002009T3 - Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib - Google Patents
Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynibInfo
- Publication number
- PL3002009T3 PL3002009T3 PL15191756T PL15191756T PL3002009T3 PL 3002009 T3 PL3002009 T3 PL 3002009T3 PL 15191756 T PL15191756 T PL 15191756T PL 15191756 T PL15191756 T PL 15191756T PL 3002009 T3 PL3002009 T3 PL 3002009T3
- Authority
- PL
- Poland
- Prior art keywords
- mutaton
- bosutinib
- compound
- treatment
- myelogenous leukemia
- Prior art date
Links
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 title 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 title 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 title 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 title 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 title 1
- 229960003736 bosutinib Drugs 0.000 title 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229960002411 imatinib Drugs 0.000 title 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93265007P | 2007-06-01 | 2007-06-01 | |
| PCT/US2008/065215 WO2008150957A2 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| EP08769857A EP2152267A2 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| EP15191756.4A EP3002009B1 (en) | 2007-06-01 | 2008-05-30 | Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3002009T3 true PL3002009T3 (pl) | 2021-12-13 |
Family
ID=39639071
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12160638T PL2478905T3 (pl) | 2007-06-01 | 2008-05-30 | Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle |
| PL15191756T PL3002009T3 (pl) | 2007-06-01 | 2008-05-30 | Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12160638T PL2478905T3 (pl) | 2007-06-01 | 2008-05-30 | Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11103497B2 (pl) |
| EP (4) | EP2478905B1 (pl) |
| JP (3) | JP5888853B2 (pl) |
| KR (1) | KR101493543B1 (pl) |
| CN (1) | CN101686973B (pl) |
| AU (1) | AU2008260070B9 (pl) |
| BR (1) | BRPI0812355A2 (pl) |
| CA (3) | CA2868899C (pl) |
| CL (1) | CL2008001577A1 (pl) |
| CY (2) | CY1115251T1 (pl) |
| DK (2) | DK2478905T3 (pl) |
| ES (2) | ES2477567T3 (pl) |
| HK (1) | HK1142812A1 (pl) |
| HU (1) | HUE055524T2 (pl) |
| IL (1) | IL202407A0 (pl) |
| MX (1) | MX2009013069A (pl) |
| PA (1) | PA8782301A1 (pl) |
| PL (2) | PL2478905T3 (pl) |
| PT (2) | PT2478905E (pl) |
| RU (1) | RU2464026C2 (pl) |
| SI (2) | SI3002009T1 (pl) |
| TW (1) | TW200908982A (pl) |
| WO (1) | WO2008150957A2 (pl) |
| ZA (1) | ZA200908480B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3002009T1 (sl) * | 2007-06-01 | 2021-09-30 | Wyeth Llc | Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib |
| EP2680844B1 (en) | 2011-03-04 | 2016-10-19 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
| KR101733665B1 (ko) * | 2015-05-06 | 2017-05-10 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물 |
| JP2022544700A (ja) * | 2019-08-22 | 2022-10-20 | バイオヘイブン・セラピューティクス・リミテッド | 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子 |
| CN115944636A (zh) * | 2022-11-01 | 2023-04-11 | 华南师范大学 | 博舒替尼在抑制i-motif结构上的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| MXPA03006412A (es) * | 2001-01-25 | 2003-10-15 | Bristol Myers Squibb Co | Metodos para administrar analogos de epotilona para tratamiento de cancer. |
| EP2290056A3 (en) * | 2001-10-05 | 2011-06-01 | Novartis AG | Mutated Abl kinase domains |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20050010780A1 (en) * | 2003-07-09 | 2005-01-13 | Kane John Richard | Method and apparatus for providing access to personal information |
| AU2004289243B2 (en) * | 2003-11-06 | 2010-07-22 | Wyeth Llc | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
| US7807159B2 (en) | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
| BRPI0610828A2 (pt) * | 2005-05-16 | 2010-07-27 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
| JP2009501523A (ja) | 2005-07-15 | 2009-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | 変異体ｓｒｃキナーゼポリペプチドを発現する個体の同定および治療方法 |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| WO2007056177A2 (en) * | 2005-11-04 | 2007-05-18 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
| SI3002009T1 (sl) * | 2007-06-01 | 2021-09-30 | Wyeth Llc | Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib |
-
2008
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en active Application Filing
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active IP Right Grant
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
-
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
-
2010
- 2010-09-28 HK HK10109282.6A patent/HK1142812A1/xx unknown
-
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
-
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
-
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3002009T1 (sl) | Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib | |
| IL251175A0 (en) | Stabilized dosage of picoplatin | |
| HK1224200A1 (zh) | 用於治療胰腺癌的藥物 | |
| PT2182936T (pt) | Terapia de redução de substrato | |
| AP2907A (en) | Viral hepatitis treatment | |
| HK1135985A1 (en) | Pyridazinones and furan-containing compounds | |
| PL2086516T3 (pl) | Przetwarzana w stanie stopionym postać użytkowa imatynibu | |
| TWI372790B (en) | Metal surface treatment composition | |
| ZA200903486B (en) | 18F-labelled folates | |
| IL205137A0 (en) | 5-cyanothienopyridines for the treatment of tumours | |
| IL200262A0 (en) | Stabilized picoplatin oral form | |
| IL201249A0 (en) | 18f - labelled folates | |
| EP1952811A4 (en) | USE OF ERIOCALYXIN B FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LEUKEMIA | |
| IL206189A0 (en) | Compound for use in the treatment of cancer | |
| EP1753400A4 (en) | PHARMACEUTICAL FOR ZIPRASIDONE | |
| PL2240172T3 (pl) | Kombinacja nilotynibu i chlorambucylu do leczenia przewlekłej białaczki limfocytowej | |
| EP2126129A4 (en) | APOPTOSIS-ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND USES THEREOF FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA | |
| EP2049096A4 (en) | METHOD FOR TREATING CELLS OF CHRONIC MYELOID LEUKEMIA | |
| GB0623492D0 (en) | Therapeutic G-quadruplex ligands | |
| GB0602857D0 (en) | The treatment of sialorrhoea | |
| GB0719613D0 (en) | The treatment of pruritis | |
| TJ27Y3 (en) | Treatment methods of chronic mesotympanitis. | |
| GB0602858D0 (en) | The treatment of sialorrhoea | |
| GB0602855D0 (en) | The Treatment Of Sialorrhoea | |
| TWM310125U (en) | Structure of wedding invitation card |